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Burkholderia are highly evolved Gram-negative bacteria that primarily infect solipeds but
are transmitted to humans by ingestion and cutaneous or aerosol exposures. Heightened
concern over human infections of Burkholderia mallei and the very closely related species
B. pseudomallei is due to the pathogens’ proven effectiveness as bioweapons, and to the
increased potential for natural opportunistic infections in the growing diabetic and immuno-
compromised populations. These Burkholderia species are nearly impervious to antibiotic
treatments and no vaccine exists. In this study, the genome of the highly virulent B. mallei
ATCC23344 strain was examined by expression library immunization for gene-encoded pro-
tective antigens. This protocol for genomic-scale functional screening was customized to
accommodate the unusually large complexity of Burkholderia, and yielded 12 new putative
vaccine candidates. Five of the candidates were individually tested as protein immunogens
and three were found to confer signiﬁcant partial protection against a lethal pulmonary
infection in a murine model of disease. Determinations of peripheral blood cytokine and
chemokine proﬁles following individual protein immunizations show that interleukin-2 (IL-2)
and IL-4 are elicited by the three conﬁrmed candidates, but unexpectedly interferon-γ and
tumor necrosis factor-α are not.We suggest that these pathogen components, discovered
using genetic immunization and conﬁrmed in a conventional protein format, will be useful
toward the development of a safe and effective glanders vaccine.
Keywords:Burkholderia,B.mallei, glanders vaccine, expression library immunization, functional genomics, genetic
immunization, DNA vaccine, subunit vaccine
INTRODUCTION
Burkholderia mallei remains an endemic pathogen in many parts
of the world including Africa, Asia, the Middle East, and South
America (Elschner et al., 2011). This Gram-negative, facultative
aerobic bacillus primarily infects solipeds, with horses considered
the natural reservoir; however, human infections occur zoonot-
ically. The course of disease depends on the route of infection.
Direct contact with the skin leads to a localized cutaneous infec-
tion called farcy. Contact with nasal or oral mucosal surfaces or
inhalation lead to a highly infectious, painful, and incapacitat-
ing disease called glanders (Nierman et al., 2004). Acute symp-
toms include coughing, fever, and the release of infectious nasal
discharge. Nodular lesions form in the lungs and ulcers develop
in the mucous membranes of the upper respiratory tract. Without
aggressive antibiotic treatment disease progresses to septicemia
and is nearly 100% fatal (Waag et al., 2005). Survivors can suffer
chronic infections of the muscle liver and spleen for up to 20 years,
and remain carriers (Whitlock et al., 2008). Even if quickly diag-
nosed, antibiotic treatments have shown low efﬁcacy and require
long regimens with multiple drugs. Moreover, no vaccine can-
didate has even progressed to a clinical trial (Kenny et al., 1999;
Leelarasamee,2004;Bondi andGoldberg,2008). These therapeutic
hurdles arise from a number of pathogen characteristics includ-
ing its ability to reside in the vacuoles of eukaryotic cells. Other
immune evading tactics, including high genomic variability (Nier-
man et al., 2004), have rendered the performance of even live
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vaccines disappointing (Ulrich et al., 2005). In addition to being a
naturally occurring disease, glanders has been used as a bioweapon
against cavalry in the American Civil War,World War I, and World
War II (Nierman et al., 2004). The severe nature of the disease
and the lack of treatment options, combined with the potential
for microbe aerosolization, have made B. mallei a member of the
Center for Disease Control and Prevention category B Priority
Agent list.
Immune correlates of protection for B. mallei are not well
developed. Its capacity to replicate inside host cells suggests that
cell-mediated responses are likely to be linked to protection. How-
ever, vaccine studies with heat-killed (HK) B. mallei strains, either
encapsulated or not, elicited mixed T helper cell type 1/type 2
responses in mice that were only weakly protective (Amemiya
et al., 2002; Whitlock et al., 2008). A live capsule-deﬁcient B.
mallei mutant was not protective; however, aerosol immunization
with a live-attenuated auxotrophic mutant conferred 50% survival
against aerosol challenge, although the mice were unable to clear
the infection. This strain was shown to elicit a Th1-skewed anti-
body response (IgG2a> to IgG1; Ulrich et al., 2005). In a recent
study, the type III secretion system protein BopA was shown to
improve survival rate, but also failed to provide sterilizing immu-
nity. It generated a strong Th1-skewed antibody response and T
cells that produced γ-interferon (IFNγ; Whitlock et al., 2010).
Although not optimal, the protection conferred by the live
B. mallei strain and BopA indicate that developing a Burk-
holderia vaccine is possible. The inherent advantage of a live-
attenuated vaccine is that no antigen identiﬁcationor development
is required, and broad antigenic diversity is possible because all
components are delivered. Molecular component vaccines are an
alternative to the use of live or killed preparations. A component
design enables immense control relative to whole-pathogen com-
positions for improving manufacture, product safety and consis-
tency, and vaccine efﬁcacy; however, antigen discovery is required.
Discovery is a considerable challenge for Burkholderia species
because of the unusual ﬂuidity and large size of their genomes, the
functional and antigenic diversity of isolates, and the exceptional
complexities of the immune responses that infection can elicit
(Holden et al., 2004;Nierman et al., 2004;U’Ren et al., 2007). These
factors suggest that if a component design is pursued, multiple
components will need to be discovered to confer robust protec-
tion. Toward this purpose, over 1500 complete bacterial genome
sequences are currently published (Relman, 2011). However, the
characteristics of a pathogen component that make it protec-
tive are poorly understood. Furthermore, a substantial portion of
the open reading frames (ORFs) in microbial databases remain
without known function (Cui et al., 2005), thereby restricting
sequence-based analyses as a method of candidate discovery.
In addition to in silico analyses, the large microbial sequence
databases can be used for the design and construction of genes
and proteins for empirical testing as antigens. New molecular
technologies have begun to provide solutions for making produc-
tion and testing possible on genomic scales. For example, through
genetic immunization (Tang et al., 1992) libraries of constructed
genes expressing the full coding capacity of a pathogen genome
can be delivered into an animal to elicit immune responses to the
pathogen proteome in a process termed expression library immu-
nization (ELI; Barry et al., 1995). These libraries are introduced
into animals as organized sub-library pools from which individual
ORFs are identiﬁed for further study based on their ability to stim-
ulate immunity against pathogen challenge. To avoid thousands of
time-consuming and bias-ridden cloning steps, we developed lin-
ear expression elements (LEEs) that can be rendered genetically
active by simply attaching desired expression sequences such as
a promoter and terminator (Sykes and Johnston, 1999b). This
study demonstrates the utility of a modiﬁed ELI method for the
discovery of B. mallei component vaccine candidates. BALB/c
mice were immunized with LEE pools expressing the B. mallei
ATCC23344 ORF-eome. To address the individual dose diluting
effects of the highly mixed ORF pools, a two-dimensional pool-
ing strategy with divergent complexities was applied. In addition,
LEEs were gene gun administered using a modiﬁed DNA/gold-
particle formulation that prevented DNA loss during bombard-
ment. Challenge–protection assays identiﬁed 12 ORFs as potential
vaccine candidates. Testing of 5 of these 12 candidates individually
in a protein subunit format conﬁrmed that three confer signiﬁcant
partial protection against pulmonary challenge and showed that
they elicit a CD4-like T cell cytokine response.
MATERIALS AND METHODS
B. MALLEI CULTURING AND GENOMIC DNA ISOLATION
Burkholderia mallei strain ATCC 23344 (China 7) was cultured
on Luria–Bertani (LB) agar plates supplemented with 4% glycerol
agar plates for 48 h at 37˚C. Isolated colonies were sub-cultured to
LB broth with 4% glycerol, and incubated at 37˚C until exponen-
tial growth phase was reached. To obtain HK inoculums, bacterial
suspensions were incubated at 85˚C for 3 h and stored at 4˚C until
use. The absence of liveB.mallei organisms in theHKpreparations
was conﬁrmed by plating 10% of the total inoculums (v/v) and
incubating these at 37˚C for 48 h. All procedures were performed
under biosafety level-3 containment.
To isolate genomic DNA, bacilli were cultured at 37˚C in LB
broth for 18 h and then pelleted at 3000–5000 g for 5–10min at
room temperature. The cells were resuspended in 1ml of buffer
B1 (with RNase A; Qiagen, Valencia, CA, USA) to obtain efﬁ-
cient lysis of the bacteria, then 20μl of lysozyme stock solution
and 45μl of Proteinase K solution were added and the samples
were incubated at 37˚C for at least 30min. Buffer 2 (0.35ml) was
added and tubes were mixed and incubated at 50˚C for 30min in
a heatblock. Lysates were added to a Qiagen Genomic-tip 500/G
puriﬁcation column and genomic DNA was extracted following
manufacturer’s instructions.
ORF AMPLIFICATION, LEE ASSEMBLY, AND GENETIC ADJUVANT
PREPARATION
The genomic sequence of the two chromosomes of B. mallei
ATCC23344 were downloaded from GenBank (accession no.
CP000010; CP000011). The genome contains a predicted total
of 5535 genes (Nierman et al., 2004). In-house software (Gene-
Splitter) was used to conﬁrm coding sequence annotations and
assign a project number to each gene. To design the project’s
ORF-eome, all genes of 1 kb or less were generated as full length
gene ORFs; genes longer than 1 kb were generated as a set of
∼800 bp long sub-genes overlapping by approximately 100 bp,
thereby increasing the number of total ORFs in the library. If
no primers could be designed to speciﬁcally amplify individual
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members of a gene family, then the whole family was permitted
to be ampliﬁed with a single oligo pair and this was recorded.
The resulting mixed PCR product was designated with a single
ORF number, thereby decreasing the total number of numerically
deﬁned ORFs relative to the annotation. Using these rules, a total
of 6630 unique B. mallei ORFs were electronically deﬁned; a cor-
responding number of ORF speciﬁc primer pairs were predicted
and obtained containing a 5′ common forward or reverse region
in addition to the ORF speciﬁc sequences. In a ﬁrst step PCR,
ORFs were ampliﬁed by 20 cycles of denaturation at 98˚C, 40 s
of annealing at 66˚C, and 2min of extension at 72˚C from ∼100
to 150 ng of B. mallei ATCC23344 genomic DNA. The MasterTaq
Kit (5′) was used with 1× Taq buffer with MgCl2, 1× Taq Mas-
ter PCR Enhancer, 0.5 units of Taq, 200μM dNTPs, and 200 nM
of ORF speciﬁc primers with a common adapter region (for-
ward primers: GGTATAGGCGGAAGCGGATTG; reverse primers:
GTGGGAGGGAGGTTAGGT) in a total volume of 10μl. Uni-
versal primers were designed for use in a second step PCR with
the common adapter region preceded by a region containing
deoxyuracil (dU) phosphoramidite bases at intervals of three
within a short 5′ stretch of the ORFs (forward primer: AGUAGUA
GUAGUAGUGGTATAGGCGGAAGCGGATTG; reverse primer:
AUGAUGAUGAUGAUGAUGTGGGAGGGAGGTTAGGT). This
reaction was set up as a 90-μl master mix containing 1× Taq
buffer with MgCl2, 1× Taq Master PCR Enhancer, ﬁve units of
Taq (Invitrogen), 200μM dNTPs, and 250 nM of the dU-universal
primers,which was then added to the 10-μl ﬁrst step PCR reaction
product. Ampliﬁcation was conducted with 5 cycles of 30 s denat-
uration at 98˚C,40 s of annealing at 50˚C, and 2min of extension at
72˚C followed by 2min of extension at 72˚C, followed by 15 cycles
of denaturation at 98˚C, 40 s of annealing at 66˚C, and 2min of
extension at 72˚C. This dU extension of the ORFs rendered them
sensitive to uracil-DNA glycosylase (UDG). This two-step ampli-
ﬁcation protocol was developed after many optimization tests in
which a large number of protocols, kits, and reagents for ampli-
fying ORFs from high-GC genomes were evaluated. Using this
protocol 5760 of the 6630 B. mallei ORFs were ampliﬁed (87%)
as high quality products (speciﬁc, correct molecular weight) of
sufﬁcient yield for LEE construction. ORF yields were quantiﬁed
ﬂuorimetrically using PicoGreen (Invitrogen). At least 1 pmol of
each ORF was generated for use in the library screen.
The cytomegalovirus (CMV) promoter and murine ubiquitin
(UB) gene sequences (1.3 kb) and the human growth hormone
(hGH) gene terminator sequence (0.6 kb) frompCMVi–UB (Sykes
and Johnston, 1999a) were ampliﬁed by PCR as two separate frag-
ments, in bulk,with primers carrying dU stretches complementary
to those present within the ORF end sequences. These sequence-
compatible PCR fragments would serve as upstream and down-
stream elements for attachment to the ORFs. In preparation, the
fragments were gel-fractionated and then puriﬁed from prepar-
ative agarose gels using QIAquick Gel extraction Kit (Qiagen),
and stored at −20˚C until LEEs were ready to be non-covalently
assembled.
In addition to this library of ORFs, two non B. mallei ORFs
were similarly prepared in the two-step protocol for use in control
group immunizations. The ﬁreﬂy luciferase (LUC) and human
α1-antitrypsin gene (AAT) genes were ampliﬁed in the ﬁrst step
from pCMViLUC+ and pCMViAAT (Sykes and Johnston, 1999b).
The same universal primers described for the library were used in
the second step ampliﬁcation. The LUC and AAT-expressing LEEs
would serve as irrelevant antigens for the challenge–protection
assays; however, the LUC and AAT LEEs would also be positive
controls for gene and genetic immunization activity, respectively.
An extra group of mice were bombarded with the LUC-expressing
LEEsprepared from the samebatchof gene gun cartridges (bullets)
as used for the immunizations. Mice were culled 24 h later and ears
were harvested to assay LUC activity (Promega, Inc.; Svarovsky
et al., 2008). The AAT-expressing LEE served as a positive con-
trol for genetic immunization efﬁciency, as immune sera was
later tested for anti-AAT reactivity by ELISA (Sykes and Johnston,
1999b).
The genetic adjuvants heat-labile toxin subunit A (LTA) and
subunit B (LTB) of E. coli were generated by cloning the respec-
tive subunit-encoding genes into the BglII and HindIII sites in
the multi-cloning site of pCMVi (Sykes and Johnston, 1999a).
LTA- and LTB-expressing covalently prepared LEEs containing the
promoter, the LTA or LTB ORF, and terminator sequences were
generated by digesting the pCMVi–LTA andpCMVi–LTBplasmids
with DraI and PvuII. These enzymes serve to linearize the plasmid
and cleave most of the plasmid backbone from the gene expres-
sion sequences. The LT-expressing LEE fragments were puriﬁed
from the pCMVi backbone by fractionation using a size-exclusion
(Sepharose) column. Fractions were analyzed on a 0.8% agarose
gel to identify the LEE fragments, and these fractions were pooled.
These plasmid sub-fragments were used for this large scale pro-
duction of elements for the library of LEEs because large scale
production of DNA by PCR is less efﬁcient than that by standard
plasmid production.
ORF POOLING, LEE ASSEMBLY, AND BIOLISTIC PARTICLE PREPARATION
The 5760 B. mallei ORFs were concentration normalized and then
pooled as ORFs using a two-dimensional 96× 48 pool grid design,
such that each dimension held all ORFs of the library. There-
fore each ORF was present once per dimension and twice within
the full grid. The ORFs within the X-dimension were partitioned
into pools by a different sorting method than the ORFs in the
Y-dimension such that each ORF resided in a pool of different
co-resident ORFs within one dimension relative to the other and
these pools were of different ORF complexities in one dimen-
sion relative to the other. Since the total DNA dose per gene gun
bombardment (shot) was constant, the effect of altering the pool
complexity was to alter the dose per ORF. The X-dimension pools
delivered 10.5 fmol of each ORF per shot and the Y-dimension
pools delivered 5.25 fmole of each ORF per shot. This was accom-
plished as follows: The ORFs were arrayed into the B–G rows of
80 separate 96-well plates. The 96 X-dimension pools were com-
prised of 60 ORF components that were pooled by taking all of the
ORFs from a speciﬁc column from each of 10 plates (for example
column 1 of plates 1–10; 1 column/plate× 6 ORFs/column× 10
plates/pool= 60 ORFs/pool). The 48Y-dimension pools consisted
of 120 ORFs that were pooled by taking all of the ORFs from a
speciﬁc row from each of 10 plates (for example the B row of
plates 1–10; 1 row/plate× 12 ORFs/row× 10 plates/pool= 120
ORFs/pool). Upstream and downstream expression elements were
added to each pool to equimolar ratio to total 40.3 pmol ORFs per
pool. The LTA and LTB adjuvant expressing ORFs were added to
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each pool in 1:9 ratio. The combined DNA mixtures represent-
ing each pool were ethanol precipitated, dissolved in water and
200μl aliquots (3+ 1 tubes) were stores at −20˚C until genetic
immunization was scheduled. UDG (NEB) treatment of DNA in
each pool was performed immediately prior to the preparation
of gene gun cartridges. For each mixture, 1.25U of UDG enzyme
was added per picomole of dU ends in pool (200U for 200 μl
aliquot). Incubation of UDG reactionwas carried out for 45min at
37˚C then 10min at 60˚C and cooling down to room temperature.
The reaction mixtures were ethanol precipitated and dissolved in
100μl water.
For biolistic immunization, LEE pools were loaded onto posi-
tively charged (polyethyleneimine,PEI)-goldmicro/nanoparticles
as previously described (Svarovsky et al., 2008, 2009) and prepared
onto gene gun cartridges for gene gun discharge.
GENETIC IMMUNIZATION AND B. MALLEI CHALLENGE
Female, 6- to 8-week-old, BALB/c mice (Harlan Sprague Daw-
ley, Inc., Indianapolis, IN, USA) were acquired and housed under
speciﬁc-pathogen-free-conditions with food and water ad libitum
on a 12-h dark/light schedule for 1week before use. The mice
were organized into groups of eight mice genetically vaccinated in
the ear skin pinnae with a Helios Gene Gun (Bio-Rad, Hercules,
CA,USA) loaded with DNA coated gold particles (Svarovsky et al.,
2009) and delivery at a heliumpressure of 350 p.s.i. Two shots were
delivered to each mouse, one in each ear. Genetic boosts with iden-
tical genetic inocula were administered at week 6 post-prime. Neg-
ative control mice were either unimmunized or immunized with a
LEE expressing the irrelevant (nonB.mallei)AAT antigen.Vaccine
control mice were vaccinated with 0.5μg of HK B. mallei [with
Interleukin-12 (IL-12)] by intraparenteral (i.p.) injection using a
25-gage syringe. Mice were challenged with 5× 105 CFU/50μl of
live B. mallei (∼2 LD50) by intranasal (i.n.) delivery 12–13weeks
following the boost. Aliquots from the inocula were plated to con-
ﬁrm the infecting dose. The challenge experiment was carried out
in four cascaded sub-experiments due to animal housing limits;
however, the same naïve, irrelevant LEE, and positive vaccine con-
trols were included in each sub-experiment. All procedures and
animal protocols used in this study were approved by the Biosafety
and IACUC committees at UTMB and conducted in either BSL-3
or ABSL-3 laboratories. Survival of mice was monitored at 12 h
intervals over time. Survival readouts were analyzed as detailed in
the Section “Results.” In the sub-experiment testing X1 through
X40, no mice died from challenge including the unimmunized
controls, indicating a sublethal dose had been administered. Since
survival could not be scored as a valid readout for these groups,
mice were sacriﬁced and lungs were weighed as a measure of the
severity of inﬂammatory disease. Challenge results are provided in
Table A1 in Appendix. Lung weight increase has been associated
with increased disease (Huppert et al., 1976). However since these
readouts could not be combined statistically with the survival data,
these groupswere excluded fromtheprotection score grid analyses.
RECOMBINANT PROTEIN PRODUCTION OF A SUBSET OF B. MALLEI
CANDIDATES
Cloning and protein expression protocols were followed as
described previously (Whitlock et al., 2010). Brieﬂy, target
sequences were subjected to bioinformatics analysis using SignalP
v.3.0 (Bendtsen et al., 2004), TMHMM v.2.0 (Krogh et al.,
2001), and PHYRE v.0.2 (Kelley et al., 2009) to identify putative
N-terminal amino acid (AA) secretion sequences, transmem-
brane domains, and homologies to published crystal structures,
respectively. Protein subcellular localization was predicted using
PSORTb v.3.0.2 (Yu et al., 2010) and CELLO v.2.5 (Yu et al.,
2004). Informatically predicted signal peptides and transmem-
brane sequences were identiﬁed so as to avoid them if possible
in the design of the ORFs for cloning into bacterial expression
constructs. This was intended to facilitate recombinant produc-
tion. The redesigned ORFs were PCR-ampliﬁed from genomic B.
mallei DNA and cloned into pET28a(+) (Novagen), or pcDNA3.1
(Invitrogen) expression vector, in frame with either an N- or C-
terminal 6× His afﬁnity tag, or both. Oligo primers introducing
speciﬁc restriction enzyme sites were purchased from Integrated
DNA Technologies. In addition to the new targets, the GroEL
gene (BMA_2001) was cloned to be produced and puriﬁed for
use as a previously characterized immunogen (Amemiya et al.,
2007).
For target protein production, E. coli host Rosetta (λDE3)
was transformed with the expression constructs. Expression was
induced by growth in Overnight Express instant TB medium
(Novagen) for 18–20 h. Bacterial pellets were lysed using 10× Cel-
Lytic B (Sigma), and 6× His-tagged proteins puriﬁed by Ni2+
afﬁnity chromatography. Puriﬁed proteins were dialyzed against
two changes of 10mM HEPES/150mM NaCl, pH 7.4, aliquoted
and stored at −80˚C. Protein concentrations were determined
using the BCA kit (Pierce) using bovine serum albumin (BSA)
as a standard. Five of the 12 candidates and the previously iden-
tiﬁed antigen GroEL (hsp60) protein were sufﬁciently produced,
with either an N- or C-terminal tag, or both, for vaccine test-
ing. BMA_2001/GroEL (residues 1–550) andBMA_2821 (residues
418–753) were produced with both N- and C-terminal His tags.
BMA_2804 (residues 17–370), BMA_A0768 (residues 20–489),
and BMA_0816 were produced with C-terminal tags. BMA_0816
was produced in three sub-fragments (residues 43–334, 35–668,
and 669–930) with C-terminal tags.
PROTEIN IMMUNIZATION AND VACCINE TESTING OF INDIVIDUAL
CANDIDATES
Female, 6- to 8-week-old,BALB/cmice (groups of 12) were immu-
nized by intramuscular (i.m.) injection with 10μg of one of
the puriﬁed candidate or control proteins, each formulated with
12.5μg immune stimulating complexes (ISCOMs) AbISCO 100
(Isconova AB, Sweden) and 12.5μg murine class C CpG motif
oligos (ODN 2395; Coley Pharmaceuticals, Wellesley, MA, USA)
in HEPES buffer (pH 7.4). A negative control group was adminis-
tered the adjuvants only. Mice were boosted at week 4 post-prime
with identical inocula and then challenged at week 7 by i.n. route
with 2 LD50 (1× 105)B.mallei ATCC23344. Deaths were recorded
twice daily. Survival results were analyzed by a log-rank statistic
test; Mantel–Haenszel survival curves were generated and plotted
(PRISM, Graphpad, Inc.). The results from the groups of mice
immunized with the same antigen but with an N versus a C-
terminal tag were similar; therefore, these data were combined
for analysis creating groups of 24 mice. The results from the N-
terminal and the central sub-proteins of BMA_816 were similarly
protective (the C-terminal sub-protein conferred no protection);
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therefore, the results from these two groups were combined for
analysis creating a group of 24 mice.
BIOPLEX ANALYSES OF CYTOKINE AND CHEMOKINE EXPRESSION
Peripheral blood sera levels of 23 cytokines and chemokines
(IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p40,
IL-12p70, IL-13, IL-17, Eotaxin, G-CSF, GM-CSF, IFN-γ, KC,
MCP-1,MIP-1α,MIP-1β, RANTES, and TNF-α) were determined
using CD4 Pro Mouse Cytokine 23-plex Assay (Bio-Rad #M60-
009RDPD). Blood samples from mice were collected 1week prior
to initial immunization (week −1) and 1week after the second
immunization (week 5 post-prime), and sera were analyzed as per
manufacturer’s instructions. Replicates of three animals per group
per time point were used to determine cytokine and chemokine
levels in the blood sera. An unpaired Student’s t -test was used to
evaluate signiﬁcance (p< 0.05).
RESULTS
DESIGN AND VALIDATION OF LINEAR EXPRESSION ELEMENTS FOR
MURINE GENETIC IMMUNIZATIONS
The B. mallei ATCC23344 genomic sequence was used to con-
struct a library of 5760 unique ORFs for construction into LEEs.
The upstream expression element carries both a CMV promoter
and the short coding sequence of a mouse ubiquitin (UB) subunit
for proteosome targeting and efﬁcient antigen processing (Sykes
and Johnston, 1999a). The downstream element carries a stop
codon in all three frames and the efﬁcient transcriptional termi-
nator from hGH gene. The tripartite molecules are annealed to
form functional LEEs (Figure 1 inset).
Before large scale library production, pilot constructs were
prepared as described above in order to validate gene vaccine
activity in mice. The genes encoding ﬁve B. mallei proteins
FIGURE 1 |Validation of ORF construction and expression in vivo. A set
of ﬁve genes encoding B. mallei proteins predicted to be secreted were
generated and constructed as linear expression elements (LEEs). These
LEEs were constructed by the same protocols as intended for use in
preparing and testing the B. mallei ORF library for vaccine candidates. Inset
cartoon shows LEE design. These ﬁve LEEs were co-delivered with LEEs
encoding the E. coli heat-labile enterotoxin subunits A and B (LTA/B) as
adjuvant by gene gun at weeks 0, 3, and 6 into groups of ﬁve mice. At week
9, mice were evaluated immunologically in challenge–protection assays.
Survival curves of immunized animals are plotted following i.n. delivery of
1×105 bacteria (2 LD50 B. mallei strain ATCC23344). The irrelevant group
was immunized similarly but with a LEE expressing the luciferase (LUC) as
a negative control for vaccine activity. This construct also served as a
positive control for LEE gene expression activity (data not shown).
predicted to be secreted via the type III secretion system (Whit-
lock et al., 2007) were used; one of these was recently tested as a
protective antigen (Whitlock et al., 2010). BopA (BMA_A1521),
BopE (BMA_A1523), BipD (BMA_A1528), BipC (BMA_A1530),
and BipB (BMA_A1531) were constructed and prepared as LEEs
for mammalian expression. They were individually delivered into
groups of ﬁve mice by gene gun together with LEEs encoding
both subunits A and B of E. coli lethal enterotoxin (LTA/B) as
genetic adjuvant (Peppoloni et al., 2003). One control group was
immunized with LEEs expressing the non-glanders (irrelevant)
luciferase (LUC) antigen with LTA/B; another control group was
not immunized. Mice were genetically immunized at weeks 0, 3,
and 6 followed by blood draws for evaluation of sera reactivity
to recombinantly produced antigens. At week 9, i.p. challenges
with 6× 107 B. mallei were conducted. Survival results indi-
cated several of the antigens conferred extended time to death;
BopA and BipD provided 20% endpoint survival from the i.p.
challenge (Figure 1). These results conﬁrm that the LEE genetic
immunization constructs are immunologically functional in vivo.
B. MALLEI EXPRESSION LIBRARY CONSTRUCTION AND STRATEGY FOR
PROTECTIVE ANTIGEN SCREENING
Bioinformatic analyses of the genome identiﬁed a number of
challenges for gene production relative to standard PCR ampli-
ﬁcation, including the high-GC content (70%) of the genome’s
coding sequences. In addition, several gene sequences displayed
high homology; speciﬁc PCR ampliﬁcation of theseORFs required
detailed analyses of gene ﬂanking sequences and individualized
reaction conditions. Further design hurdles included the large
number of transposable elements, bacterial introns, and overlap-
ping transcripts that are found throughout the genome. Using
the optimized reagents and protocol conditions, 5760 of the 6630
enumerated ORFs were ampliﬁed and constructed into LEEs,
representing 87% of the coding capacity of B. mallei.
The ELI screen was designed to assay the vaccine potential of
each B. mallei library component twice. This was done by distrib-
uting the complete library of 5760 ORFs into two immunization
pools, by independent strategies that were designated X and Y.
The feasibility of performing this multiplexed protection exper-
iment design for antigen discovery was previously demonstrated
(Stemke-Hale et al., 2005; Borovkov et al., 2009). For this project,
each of the X-pools held 60 ORFs, creating 96 X’s; each of the
Y-pools held 120 ORFs, creating 48 Y’s. Every ORF resided once in
the X library and once in the Y library, but at doses that differed
by twofold. Unlike earlier strategies, this enabled sensitivity to be
optimized in the X-dimension and screening efﬁciency to be opti-
mized in the Y-dimension. Two-dimensional matrix analyses of
these organized distributions of ORFs would enable a single ani-
mal experiment of 144 groups to be used to infer which individual
ORFs were responsible for disease protection.
GLANDERS ELI SCREEN
The inocula comprising the X and Y LEE pools were co-delivered
with the LTA/B genetic adjuvant into groups of eight BALB/c
mice by gene gunon charged-goldmicro/nanoparticles (Svarovsky
et al., 2009). Genetic boosts were delivered at week 6 post-prime
using the same inocula. At week 18 post-prime, a lethal i.n. chal-
lenge of B.mallei (2 LD50)was administered;miceweremonitored
www.frontiersin.org November 2011 | Volume 2 | Article 227 | 5
Whitlock et al. Functional screening for B. mallei vaccine candidates
and deaths were recorded twice daily. As negative controls, naïve
mice were not immunized and an irrelevant antigen group was
administered anAAT-expressing LEE.As a positive control for pro-
tection, a group of mice was i.p. immunized with a HK B. mallei
preparation with IL-12p70 as adjuvant.
Protection scores for all of the test and control groups were
determined by recording the hours survived by each mouse, then
deriving an average survival time for each group (Table A1). Con-
ﬁdence intervals (95%) and ANOVA scores were calculated to
generate corresponding p-values for each test group relative to
controls. In the X library of ORF-expressing LEE pools, X57, X59,
and X89 conferred signiﬁcantly extended times to death; within
the Y library pools Y15 and Y19 were signiﬁcantly protective
(p< 0.05). These results are detailed in Table 1. In addition to
the protection score analysis, log-rank Mantel–Haenszel survival
curves were generated, with respective p-values calculated rela-
tive to controls (Prism 4.0, Graphpad Software, San Diego, CA,
USA). This analysis indicated that mice immunized with pool Y24
also displayed signiﬁcant extended time to death. Endpoint group
survival rates are shown alongside each group’s survival curve sta-
tistic in Table 1. Animals immunized with pool X89 showed 87.5%
endpoint survival following lethal i.n. infection. Immunization
with pools X57 and X59 provided animals 75% endpoint survival
following the i.n. challenge. The mouse groups administered the
positive vaccine control (HK B. mallei with IL-12p) displayed 100
and 62.5% survival rates in the X and Y challenge assays, respec-
tively; the irrelevant antigen groups showed 25 and 0% survival in
X and Y experiments, respectively. These survival curves are dis-
played in Figure 2; the top panel displays signiﬁcantly different test
group and also control group survival curves from the X challenge
assay and the bottom panel similarly shows the Y challenge assay
survival curves.
Together, the protection score and survival curve analyses indi-
cated that three X-pools and three Y-pools were signiﬁcantly
protective. However, the pooling strategy of the two-dimensional
screen designated Y-pools with twice the ORF complexity of the
Table 1 | Analyses of ELI challenge–protection screen.
Protection score
(p-value)
Protection
rank
Endpoint survival (%)
(p-value)
X-POOLS
X89 423 (0.003) 1 87.5 (0.006)
X57 372 (0.03) 2 75 (0.029)
X59 365 (0.04) 3 75 (0.05)
X75 321 (0.17) 4 62.5 (0.137)
X95 318 (0.18) 5 62.5 (0.158)
X76 317 (0.20) 6 62.5 (0.156)
Irrelevant 126 (0.59) 25
HK+ IL-12 456 (0.0005) 100
Y-POOLS
Y19 270 (0.02) 1 50 (0.027)
Y15 269 (0.02) 2 50 (0.08)
Y24 233 (0.10) 3 37.5 (0.05)
Irrelevant 146 (0.89) 0
HK+ IL-12 336 (0.0003) 62.5
X-pools (120 versus 60 ORFs). Since a matrix analysis would be
most informative if a similar number of ORFs were crossed from
each dimension (library), the X-pools ranked 4, 5, and 6 (X75,
X76, and X95 with p-values of 0.17, 0.20, and 0.018, respectively)
were taken into the cross-hair analyses. Their protection scores,
survival rates, and statistics are provided in Table 1.
IDENTIFICATION AND TESTING OF SCREEN-INFERRED PROTECTIVE
ANTIGENS
A matrix analysis was performed to pinpoint any antigens that
conferred protection as a constituent within both its X-pool and
Y-pool inocula. This was done by comparing the list of ORFs
comprising the subset of X-pools selected for further evaluation
FIGURE 2 | Screening of the B. mallei ORF-ome for vaccine candidates
by ORF-pool immunization and challenge–protection assay. Groups of
eight mice were immunized once in each ear pinna with 1μg dose by gene
gun. Each discharge carried a pool of B. mallei ORFs as LEEs (0.9μg) and
the genetic adjuvant LTA/B (0.1μg). The LTA and LTB-expressing LEEs were
mixed 1:5 (0.08 and 0.02μg, respectively). Two libraries of 5750 ORFs,
labeled X andY, were partitioned into 96 pools of 60 ORFs (X-pools) or 48
pools of 120 ORFs (Y-pools). Controls were heat-killed (HK) B. mallei, the
non B. mallei antigen α1-antitrypsin (AAT), and naïve mice. Boosts were
similarly administered at week 6. A 2 LD50 (1×105) dose of live B. mallei
ATCC23344 was administered i.n. at week 10 and death was monitored
twice daily. Survival curves were generated for all groups; however, only
the curves corresponding to statistically protective groups (p<0.05) and
controls are plotted for clarity. Top graph displays results from animals
immunized with protective pools from the X library. Bottom graph displays
the survival courses of mouse groups administered the protective pools
from theY library.
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to the list of ORFs comprising the Y-pools selected for evaluation.
Furthermore, each ORF was considered to represent its full length
target gene. This was done because a protective antigen often car-
ries multiple protective epitopes (Crowe et al., 2010), and these are
likely to rank differently in potency from one species to another as
a result of divergent antigen presentation molecules and processes.
Therefore, identiﬁcation of any portion of a gene is likely to indi-
cate a useful target antigen, as opposed to merely a target epitope.
Twelve B. mallei genes were identiﬁed by this overlapping pool
matrix analysis. These candidates are enumerated in Table 2 along
with their resident pools within the screen and any predicted
protein functions or homologies found in existing databases.
To evaluate how genetic immunization leads might translate
into more conventional protein subunit vaccine formulations,
the 12 new gene vaccine candidates were subjected to structural
analysis in preparation for testing in a new round of challenge–
protection assays as individually administered protein inocula.
Many of the target proteins carried multiple predicted trans-
membrane helices that would make recombinant protein pro-
duction difﬁcult. These were excluded from the expression con-
structs in favor of regions predicted to be immunogenic (see
Materials and Methods). The BMA_0816 gene was cloned and
expressed as three sub-fragments because of its large size. Five
candidates (BMA_A0712, BMA_A0768, BMA_0816, BMA_2804,
BMA_2821) and the previously described immunogen GroEL
(BMA_2001;Amemiya et al., 2007) were bacterially producedwith
N- and/or C-terminal His tags and puriﬁed by standard nickel-
afﬁnity chromatography. Each of the six proteins was delivered
i.m. with ISCOMs and murine class C motif CpG oligos as adju-
vant into groups of 12 BALB/c mice. Boosts were administered at
Table 2 | Individual B. mallei vaccine candidate genes identified from
matrix analysis of the ELI challenge–protection assays.
ELI-derived
vaccine
candidate
Predicted function/homology Resident
ELI pools
BMA_A1219 Tetratricopeptide repeat protein X95; Y24
BMA_A1678 Selenocysteine-speciﬁc translation
elongation factor
X76; X95;
Y24
BMA_A1678 Putative CpaE protein (pilus assembly) X76; Y24
BMA_A1325 Major facilitator family sugar transporter X95; Y24
BMA_A07121 Major facilitator superfamily protein X75; Y24
BMA_A07682 Mannitol dehydrogenase family protein X57; Y19
BMA_A0950 Major facilitator family transporter; MerR
family transcriptional regulator
X89; Y24
BMA_28212 Toxin secretion ABC transporter, ATP-binding
protein (colicinV processing peptidase)
X75; Y15
BMA_28041 Molecular chaperone, Hsp70 X75; Y19
BMA_2468 Glyceraldehyde-3-phosphate dehydrogenase,
type I
X57; Y24
BMA_0092 Peptide ABC transporter, ATP-binding protein X59; Y24
BMA_08162 Maltooligosyl trehalose synthase (putative
glycosyl hydrolase)
X89; Y24
1Candidates tested individually are shown in boldface.
2Vaccine candidates found to be protective are indicated in red type.
week 4 and then the mice were challenged with live B. mallei (2
LD50) at week 7. Survival was monitored and recorded twice daily.
Protection was assessed by generating Mantel–Haenszel sur-
vival curves and deriving a log-rank statistic as described above.
The results plotted in Figure 3 show that three of the ﬁve tested
candidates and GroEL were conﬁrmed as conferring partial pro-
tection. Immunization with the protein encoded by BMA_A0768
provided 25% (3/12) endpoint survival while GroEL immu-
nization provided 12.5% (3/24) endpoint survival and both
displayed signiﬁcantly extended times to death (p= 0.025 and
p< 0.001, respectively). The proteins encoded by BMA_2821 and
BMA_0816 also conferred signiﬁcantly extended times to death
(p = 0.0023 and p< 0.0001, respectively) relative to adjuvant only
immunized controls. The three signiﬁcantly protective candidates
(BMA_A0768,BMA_2821, and BMA_0816) are highlighted in red
in Table 2.
ELI VACCINE CANDIDATES ELICIT SERUM CYTOKINE AND CHEMOKINE
RESPONSES
Blood was drawn from the animals described above, immunized
with the ﬁve B. mallei protein antigen candidates or the adjuvant
control, 1 week prior to immunization (week −1 relative to prime)
as a baseline for each animal and then 1week after the booster
(=week 5 post-prime) as a measure of vaccine elicited responses.
Measuring levels at these two time points was designed to dis-
play a proﬁle of the hosts’ responses to vaccination (Figure 4).
The inﬂuence of the adjuvant on host responses was measured
by comparing the pre-immunization proﬁles to that of the con-
trol sera, which was not drawn from naïve mice but from mice
immunized with adjuvant only. Prior to immunization, GM-CSF
(BMA_0768) andMIP-1β (BMA_0768) showed elevated levels rel-
ative to the adjuvant-immunized control sera; whereas IL-12p70
(BMA_A0712) was signiﬁcantly lower in one of the pre-immune
FIGURE 3 | Evaluation of a subset of the vaccine candidates identified
by ELI, tested individually. Groups of 12 BALB/c mice were i.p. injected
with the ﬁve candidates and GroEL (BMA 2001) delivered as recombinant
bacterially produced proteins. These were formulated with ISCOMs and
CpG’s as adjuvants (adjuvant). Boosts were administered at week 4
post-prime and challenged by i.n. route with 2 LD50 (1×105) B. mallei
ATCC23344 at week 7. Survival was monitored, recorded and analyzed as
described in the Section “Materials and Methods.” The Mantel–Haenszel
survival curves for the control groups and for the three test groups that
displayed statistically signiﬁcant protection (p<0.05) are plotted. GenBank
BMA gene numbers are shown.
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FIGURE 4 | Continued
Frontiers in Microbiology | Cellular and Infection Microbiology November 2011 | Volume 2 | Article 227 | 8
Whitlock et al. Functional screening for B. mallei vaccine candidates
FIGURE 4 | Bioplex analyses of proinflammatory cytokines elicited in
peripheral blood of immunized versus unimmunized mice. Blood was
drawn (i) 1week prior to immunization and (ii) 1week post booster
immunization (=5weeks post-prime) of the mice described in Figure 3.
Results from these time points are graphed on the left (pre-immunization)
and right (post-immunization) panels. Control sera were drawn from
adjuvant-immunized mice. Replicates of three animals per group per time
point were used to determine the level of cytokine or chemokine indicated
above each pair of graphs (A) through (G). Sera were collected and
analyzed per manufacturer’s instructions. Unpaired Student’s t -test was
utilized to determine signiﬁcance (p<0.05). Error bars are SD with group
sera.
sera groups relative to the sera from adjuvant expose mice. This
indicates that IL-12p70 may be elicited by the ISCOM and CpG
formulation alone. Post-immunization, IL-2 levels were signiﬁ-
cantly elevated in sera from mice immunized with three of the
ﬁve antigen candidates (BMA_0816, BMA_A0712, BMA_0768),
two of which were protective (Figure 3). IL-4 (BMA_0816) and
MIP-1β (BMA_A0712) were also signiﬁcantly different (p< 0.05)
from the adjuvant-immunized control sera levels, with IL-4 ele-
vated and MIP-1β reduced. These levels represent antigen-speciﬁc
activity elicited by the vaccine candidates.
DISCUSSION
A functional genomics vaccine candidate screen does not need to
assume anything about the properties or characteristics of protec-
tive antigens. However the screen presented here does assume that
a protective gene can be detected among many simultaneously
expressed ones. Support for this assumption lies in its parallel
with the antigenic complexity of a live or whole-pathogen vac-
cine, or a pathogen infection, situations in which the immune
system is exposed to a mixture of many antigens. We used ELI
to directly test the B. mallei ORF-eome for protective compo-
nents by genetic immunization followed by lethal challenge. A
two-dimensional, matrix analysis of a genomic-scale protection
assay following vaccination with pools of ORFs indicated 12 gene
candidates as being responsible for conferring survival rates as high
as∼90%against i.n. challenges. Five of these 12 vaccine candidates
were produced as proteins and tested as individual antigens in the
challenge–protection assays; three were found to provide signiﬁ-
cant, partial protection from a lethal pulmonary infection with B.
mallei.
The protection level measured following immunization with
any of the ﬁve tested protein candidates was lower than that
achieved by the ORF pools in which the candidates were origi-
nally resident. The simplest explanation for this outcome is that
the more highly protective candidates were among the seven
untested of the 12 matrix-inferred candidates. Even for the ﬁve
tested candidates, only the portions of the target proteins selected
for recombinant expression by bioinformatics were administered;
more strongly protective epitopes may have been unintentionally
excluded. Alternatively the antigen delivery format, which differed
between the two rounds of challenge–protection assays, may be
critical. First, the genetic immunization constructs expressed the
antigens endogenously within the skin cells of the host, and these
constructs carried proteasomal targeting (UB) sequences intended
to promote cellular immune responses against the UB-fused anti-
gen. By contrast, the candidates were redesigned in the second
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round without UB fusion or their natural secretory leader pep-
tides for ex vivo protein production.We had elected to reformulate
the candidates from genes into proteins for the secondary round
of vaccine testing because of the generally higher level of accep-
tance of this more traditional subunit vaccine format. Namely,
several protein-based vaccines have already been FDA approved
(http://www.fda.gov/BiologicsBloodVaccines/Vaccines/Approved
Products/UCM093833) while gene vaccines are at this time still
in trials. Protein formats have been shown to promote T helper
cell 2-like (Th2) responses and antibody production, relative to
in vivo produced antigen (Chow et al., 1998; Iborra et al., 2007).
These responses may not be as protective as Th1 responses against
B. mallei. As a second difference in delivery format between the
two rounds, themixed versus individual context of the antigenmay
be relevant. The signiﬁcance of this format distinction is consis-
tent with several previous ELI screens in which all candidates were
tested, and all tested as genes in both initial and secondary screens.
In these studies, the mixed pool inocula were frequently more pro-
tective than the individually evaluated candidates (Stemke-Hale
et al., 2005; Li et al., 2006; Borovkov et al., 2009), as found in
this work.
We suggest that the complexity of the ORF pools is important.
In this project, we intentionally designed a grid with differing
complexities (either 60 or 120 in the X and Y-pools respectively)
potentially capturing the undetermined effects of antigen dose,
complexity, and competition on immunity. If there were neither
negative nor positive interactions among the constituents of the
mixed inocula, then we anticipated that maximizing dose would
be most important in maximizing any response elicited. Since we
delivered constant total genetic doses, this would mean that the
lower pool complexity (higher individual ORF doses) of the X-
pools would be advantaged over the Y-pools. However the average
levels of protection conferred by the X versus the Y-pools, relative
to HK B mallei and irrelevant antigens were similar. This indicates
that dose was not a strong factor in the survival readout. Alter-
natively, if immunological interactions do occur among the pool
constituents, then an ORF’s individual performance level may be
evaluated relative to that within a pool; however, the performance
of an ORF in two different pools of two different complexities
cannot be quantitatively interpreted. Antigenic competition has
been well described among co-delivered protein antigens (Adorini
et al., 1989); however, a range of results have been reported for
immune interactions among co-delivered genetic antigens (Braun
et al., 1998; Sedegah et al., 2004; Hirao et al., 2011). A combination
of competitive and cooperative activities among the antigen pool
components would have opposing effects that would blur minor
differences in antigen dose. This is consistent with our observa-
tions. Nonetheless, the performance of both the X and Y antigen
poolswere reproducibly superior relative to that of the individually
administered antigens. These results suggest that the overarching
effect of gene vaccine complexity is cooperative. The three con-
ﬁrmed individual candidates may play a critical role as a speciﬁc
antigen, while one or more of the remaining constituents of their
highly protective resident pools may provide non-speciﬁc, or even
additional speciﬁc, immunological help andmodulation.Thismay
be addressed in vaccine development in a number of ways. For
example, a small set of cooperatively acting components may be
identiﬁed in future studies that are highly effective. Protection
levels may also be enhanced by immunomodulators that direct
responses to those determined to be most effective. Mixed modal-
ity immunization regimens such as DNA-prime/protein- or live
vectored-boosts may serve to widen the breadth of responses to
facilitate greater protection levels. Notably, the ELI screen was
done by genetic immunization and a long immunization regimen
(18weeks), whereas the individual components were delivered
as proteins in an abbreviated regimen (7weeks). Perhaps their
combination in a mixed modality prime-boost regimen, and an
extended immunization period, would be productive.
Bioplex determinations of a set of 23 cytokine and chemokines
identiﬁed IL-2 as the principal cytokine elicited by the vaccine
candidates. IL-2 was signiﬁcantly elevated relative to controls in
the sera from three of the ﬁve groups of mice immunized with
individual protein antigens; two of these groups displayed signiﬁ-
cant protection from challenge. IL-4 was also signiﬁcantly elevated
in sera from mice immunized with one of the tested candidates
that conferred protection. Notably, the cytokine proﬁle elicited by
these subunit vaccines is divergent from those stimulated follow-
ing exposure to HK B. mallei, or the BopA subunit, which includes
IFNγ and TNFα τ cell secretion (Whitlock et al., 2008, 2010). This
suggests that improved protection might be achieved by either
formulating these antigens with a different adjuvant or prepar-
ing the antigens in another format (such as genes or gene pools,
or live vector) that would modulate the cytokine proﬁle closer to
that elicited by other vaccines. However, the strong CD4 T cell
and antibody response indicated by expression of IL-2 and IL-4
is consistent with the importance found for B cells in the pro-
tective response to HK B. mallei (Whitlock et al., 2008). Notably,
class C motif CpG oligos were selected as the adjuvant in this
study because of the role demonstrated for antibodies in addition
to cell-mediated responses in clearing B. mallei infections (Bondi
and Goldberg, 2008). A more divergent explanation is that these
three new antigens direct the host immune system to generate a
unique protective response not engendered by previously tested
subunits or by the pathogen itself.
In the microbial world, the genomes of Burkholderia species
rank as some of the most complex, carrying nearly as many
base pairs as a eukaryotic yeast genome (Holden et al., 2004;
Nierman et al., 2004). Through the empirical discovery approach
described here, we have identiﬁed 12 new vaccine candidates for
further evaluation (Table 2). A number of these pathogen com-
ponents were unlikely to have been selected informatically from
the genome since the pSORT B-predictions indicated cytoplas-
mic localizations (Table 3). The preliminary testing of a subset
of only ﬁve of these candidates established that three conferred
signiﬁcant protection against a pulmonary challenge with virulent
B. mallei bacilli. Of these three protective candidates, two are pre-
dicted to encode cytoplasmic enzymes. First, BMA_A0768 displays
homology to a mannitol dehydrogenase (MTD) gene, encoding
a member of an oxidoreductase family. Mannitol and MTD are
known to play roles in host defense and pathogen counter-defense
(Jennings et al., 1998). Second, BMA_0816 is homologous to a
maltooligosyl trehalose synthase gene, encoding an enzyme that
catalyzes transglycosylations (Nakada et al., 1995). In contrast to
these genes, the third vaccine candidate, BMA_2821, encodes a
membrane protein. It shows homology to a member of the ATP-
binding cassette (ABC) transporter family that secretes the peptide
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Table 3 | Characteristics of individually protective subunit vaccine
candidates.
B. mallei
vaccine
candidate
Cellular
location
Percentage
identity to
Bpm 96243
Survival curve
significance,
p-value
BMA_A0768 Cytoplasmica,b 99.8 0.025
BMA_2821 Inner membranea,b 99.7 0.002
BMA_0816 Cytoplasmica,b/outer
membraneb
99.5 <0.0001
aDetermined by PSORTb v.3.0.2.
bDetermined by CELLO v.2.5.
antibiotic colicinV (Zhong et al., 1996).Colicin is encodedon a vir-
ulence plasmid and the ABC efﬂux transporter secretes it (Waters
and Crosa, 1991). By conventional criteria, this surface-located
virulence-factor secreting protein might have been classiﬁed as
a putative protective antigen. Notably, another ABC transporter
was within the set of 12 ELI-derived candidates, in addition to a
sugar transporter; however,neither of theseORFs (BMA_0092 and
BMA_A1325, respectively) was individually tested in the vaccine
assay.
Sequence alignments of the protective B. mallei ORFs to the
B. pseudomallei K96243 (Bpm 96243) strain homologs show a
very high percentage of identity (Table 3), suggesting that these
antigens may be able to cross-protect against B. pseudomallei
infection. Further characterization and optimizations of the pro-
tective immune responses induced by these new candidates, and
exploration of the remaining candidates, may reveal novel path-
ways to immunity against B. mallei, and possibly B. pseudomallei.
In summary our results provide a basis for the development
of a safe and effective Burkholderia vaccine, comprised of a set
of genome-encoded pathogen components, against pulmonary
glanders disease.
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Table A1 | Challenge protection results from ELI screen.
Group Protection score (p-value) Rank
Y1 129 (0.63) 31
Y2 131 (0.66) 26
Y3 81 (0.15) 46
Y4 177 (0.62) 14
Y5 107 (0.35) 37
Y6 179 (0.60) 9
Y7 197 (0.38) 4
Y8 177 (0.62) 12
Y9 131 (0.66) 26
Y10 134 (0.70) 24
Y11 149 (0.93) 19
Y12 110 (0.38) 36
Y13 81 (0.15) 46
Y14 131 (0.66) 26
Y15 269 (0.02) 2
Y16 81 (0.15) 46
Y17 131 (0.66) 26
Y18 92 (0.22) 41
Y19 270 (0.02) 1
Y20 177 (0.62) 14
Y21 146 (0.89) 18
Y22 95 (0.24) 39
Y23 180 (0.58) 7
Y24 233 (0.11) 3
Y25 138 (0.77) 32
Y26 135 (0.72) 22
Y27 86 (0.17) 43
Y28 93 (0.23) 41
Y29 134 (0.70) 21
Y30 125 (0.57) 33
Y31 174 (0.67) 17
Y32 84 (0.19) 44
Y33 96 (0.25) 38
Y34 176 (0.65) 16
Y35 84 (0.16) 44
Y36 179 (0.60) 9
Y37 131 (0.66) 26
Y38 191 (0.45) 5
Y39 179 (0.60) 9
Y40 138 (0.77) 20
Y41 135 (0.72) 22
Y42 182 (0.56) 6
Y43 134 (0.70) 24
Y44 180 (0.58) 8
Y45 119 (0.49) 35
Y46 177 (0.62) 12
Y47 93 (0.23) 40
Y48 126 (0.59) 34
Naïve 1 146 (0.89)
Irrelevant 126 (0.59)
Vaccine 1 336 (0.0003)
Vaccine 2 456 (<0.0001)
Group Protection score (p-value) Rank
X41 222 (0.85) 53
X42 128 (0.09) 52
X43 126 (0.09) 55
X44 83 (0.02) 56
X45 129 (0.10) 51
X46 174 (0.35) 46
X47 228 (0.92) 28
X48 186 (0.45) 39
X49 177 (0.37) 45
X50 231 (0.96) 23
X51 269 (0.59) 21
X52 273 (0.54) 13
X53 276 (0.51) 10
X54 230 (0.94) 26
X55 273 (0.54) 13
X56 273 (0.54) 13
X57 372 (0.03) 2
X58 270 (0.57) 18
X59 365 (0.04) 3
X60 183 (0.42) 40
X61 227 (0.91) 30
X62 210 (0.71) 37
X63 231 (0.96) 24
X64 291 (0.37) 7
X65 183 (0.42) 54
X66 180 (0.40) 41
X67 159 (0.24) 49
X68 222 (0.85) 35
X69 180 (0.40) 41
X70 180 (0.40) 41
X71 134 (0.11) 50
X72 221 (0.83) 36
X73 237 (0.96) 22
X74 273 (0.54) 13
X75 321 (0.17) 4
X76 317 (0.20) 6
X77 180 (0.40) 41
X78 224 (0.87) 33
X79 270 (0.57) 17
X80 270 (0.57) 18
X81 189 (0.48) 38
X82 173 (0.33) 47
X83 176 (0.36) 48
X84 270 (0.57) 18
X85 230 (0.94) 25
X86 276 (0.51) 10
X87 276 (0.51) 8
X88 227 (0.91) 30
X89 423 (0.003) 1
X90 224 (0.87) 33
X91 227 (0.91) 30
X92 276 (0.51) 8
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X93 276 (0.51) 10
X94 228 (0.92) 29
X95 318 (0.19) 5
X96 230 (0.94) 26
Naïve 1 224 (0.87)
Naïve 2 183 (0.42)
Irrelevant 192 (0.51)
Vaccine 456 (0.0005)
Group Average spleen weight (g) Rank
X1 1.43 28
X2 1.25 18
X3 1.67 38
X4 1.53 33
X5 1.04 8
X6 1.13 11
X7 1.19 15
X8 1.46 29
X9 1.13 11
X10 1.02 6
X11 1.51 32
X12 1.29 20
X13 1.32 22
X14 1.61 34
X15 1.30 21
X16 1.62 35
X17 1.62 35
X18 1.50 31
X19 1.62 35
X20 1.35 25
X21 1.49 30
X22 1.71 39
X23 1.20 17
X24 1.90 40
X25 1.07 9
X26 1.18 14
X27 1.19 15
X28 1.33 24
X29 1.02 7
X30 1.01 5
X31 1.32 22
X32 0.91 1
X33 1.27 19
X34 1.15 13
X35 0.97 4
X36 0.95 3
X37 0.91 1
X38 1.36 26
X39 1.11 10
X40 1.36 26
Naïve uninfected 1.00
Naïve infected 1.25
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